This systematic review examines the current landscape of Post-Traumatic Stress Disorder (PTSD) treatments and positions MDMA-assisted therapy within that context. It highlights a critical issue: the evidence base supporting commonly used PTSD treatments is often heterogeneous, meaning that the strength and consistency of research findings vary considerably across different therapies. This heterogeneity makes it difficult to definitively conclude the superiority of one treatment over another...

The term "Psychedelic Renaissance" frequently accompanies discussions of psychedelics for mental health. This article seeks to evaluate the validity of characterizing this renewed interest as a genuine paradigm shift. Paradigm shifts, in a scientific context, represent fundamental changes in accepted theories and practices. The authors likely assess the current state of psychedelic research against this standard, considering factors like the strength of clinical evidence for efficacy, the...

This research focuses on the use of psilocybin-assisted therapy (PAT) for treating major depressive disorder (MDD). PAT involves administering psilocybin, a psychedelic compound found in certain mushrooms, in conjunction with psychological support from trained therapists. The study likely employs randomized controlled trials (RCTs), which are considered the gold standard for evaluating the effectiveness of interventions. RCTs randomly assign participants to either a treatment group receiving...